Applied Therapeutics announced the appointment of Dale Hooks as Chief Commercial Officer, replacing Adam Hansard, effective immediately. Hooks will be responsible for leading Applied’s commercial preparations for the potential launch of govorestat for the treatment of Classic Galactosemia and SORD. Most recently, he served as Vice President, Global Commercial Operations at Reata Pharmaceuticals, from 2019 until its acquisition by Biogen in 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLT:
- Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
- Applied Therapeutics to present data from study of caficrestat in DbCM
- Applied Therapeutics down 11% after extended FDA review for govorestat NDA
- Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
- Applied Therapeutics: FDA extends review period for NDA for govorestat